Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance, Organon to Develop Dx for Psychiatric Drug Response

NEW YORK, July 18 (GenomeWeb News) - Genaissance Pharmaceuticals and Organon will jointly study genetic markers related to drug response in certain undisclosed psychiatric disorders, and plan to develop diagnostics based on the resulting data, the companies said today.

 

Under the agreement, Organon will license Genaissance's HAP technology and will pay the company fees for genotyping samples from clinical trials and for research. Genaissance will also provide DNA isolation and sample banking for the trials.

 

In addition to providing services, Genaissance has certain rights to develop and commercialize genetic tests accompanying therapy. Both companies will share royalties on revenues generated from such tests.

 

Organon, a business unit of Akzo Nobel, is based in Roseland, NJ. It focuses on reproductive medicine, psychiatry, and anesthesia.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more